Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 23, 2020updated 15 Apr 2020 1:24pm

University Hospitals in US to conduct coronavirus clinical trials

University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised due to pneumonia.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

University Hospitals in Cleveland, US is set to conduct two clinical trials of remdesivir to treat adult Covid-19 patients hospitalised due to pneumonia.

Remdesivir is an investigational antiviral drug developed by Gilead Sciences. The drug showed a promising profile with good safety and tolerability in animal studies.

Gilead is currently assessing the drug in several clinical trials for the treatment of novel coronavirus infection.

The University Hospitals trials will be conducted by the UH Clinical Research Center.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

UH Cleveland Medical chief clinical and scientific officer and president Daniel Simon said: “Our UH research team has worked closely with the manufacturer, Gilead, in recent days to secure the studies. We are grateful to be one of the first sites in the US to participate in these clinical trials.

“Both trials are now approved by the Food and Drug Administration (FDA) and our Institutional Review Board, and we are expecting shipment of the experimental drug remdesivir in the next couple of days.”

One trial will involve patients with moderate illness and will compare the efficacy of two remdesivir regimens to standard of care.

The efficacy will be determined as the proportion of patients discharged on or before day 14 of hospitalisation.

Meanwhile, the second trial will recruit patients with more severe illness who may need intensive care.

The second study’s primary objective is the efficacy of two different dosing regimens of the drug and their ability to normalise patients’ temperature and oxygen saturation to day 14.

All trial participants will be administered with remdesivir intravenously and will be randomised to five days or ten days of treatment regimen.

University Hospitals hopes to open the studies at UH Ahuja, Parma, and St John medical centres. The organisation is also exploring other trials.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU